These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

165 related items for PubMed ID: 29708843

  • 21. Cost-effectiveness analysis of universal influenza vaccination with quadrivalent inactivated vaccine in the United States.
    Clements KM, Meier G, McGarry LJ, Pruttivarasin N, Misurski DA.
    Hum Vaccin Immunother; 2014; 10(5):1171-80. PubMed ID: 24609063
    [Abstract] [Full Text] [Related]

  • 22. Immunogenicity, reactogenicity and safety of an inactivated quadrivalent influenza vaccine candidate versus inactivated trivalent influenza vaccine: a phase III, randomized trial in adults aged ≥18 years.
    Kieninger D, Sheldon E, Lin WY, Yu CJ, Bayas JM, Gabor JJ, Esen M, Fernandez Roure JL, Narejos Perez S, Alvarez Sanchez C, Feng Y, Claeys C, Peeters M, Innis BL, Jain V.
    BMC Infect Dis; 2013 Jul 24; 13():343. PubMed ID: 23883186
    [Abstract] [Full Text] [Related]

  • 23. The cost-effectiveness of trivalent and quadrivalent influenza vaccination in communities in South Africa, Vietnam and Australia.
    de Boer PT, Kelso JK, Halder N, Nguyen TP, Moyes J, Cohen C, Barr IG, Postma MJ, Milne GJ.
    Vaccine; 2018 Feb 08; 36(7):997-1007. PubMed ID: 29373192
    [Abstract] [Full Text] [Related]

  • 24. A randomized trial of candidate inactivated quadrivalent influenza vaccine versus trivalent influenza vaccines in children aged 3-17 years.
    Domachowske JB, Pankow-Culot H, Bautista M, Feng Y, Claeys C, Peeters M, Innis BL, Jain V.
    J Infect Dis; 2013 Jun 15; 207(12):1878-87. PubMed ID: 23470848
    [Abstract] [Full Text] [Related]

  • 25. Cost-effectiveness analysis of switching from a trivalent to a quadrivalent inactivated influenza vaccine in the Peruvian immunisation programme.
    Bellier L, Petitjean A, Sarazu T, Tresierra J, Lopez JG.
    Vaccine; 2021 Jul 05; 39(30):4144-4152. PubMed ID: 34130885
    [Abstract] [Full Text] [Related]

  • 26. Immunogenicity and safety of quadrivalent versus trivalent inactivated influenza vaccine: a randomized, controlled trial in adults.
    Beran J, Peeters M, Dewé W, Raupachová J, Hobzová L, Devaster JM.
    BMC Infect Dis; 2013 May 20; 13():224. PubMed ID: 23688546
    [Abstract] [Full Text] [Related]

  • 27. Public health and economic impact of seasonal influenza vaccination with quadrivalent influenza vaccines compared to trivalent influenza vaccines in Europe.
    Uhart M, Bricout H, Clay E, Largeron N.
    Hum Vaccin Immunother; 2016 Sep 20; 12(9):2259-68. PubMed ID: 27166916
    [Abstract] [Full Text] [Related]

  • 28.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 29. Impact of quadrivalent influenza vaccine on public health and influenza-related costs in Australia.
    Jamotte A, Chong CF, Manton A, Macabeo B, Toumi M.
    BMC Public Health; 2016 Jul 22; 16():630. PubMed ID: 27449665
    [Abstract] [Full Text] [Related]

  • 30. Review of seasonal influenza in Canada: Burden of disease and the cost-effectiveness of quadrivalent inactivated influenza vaccines.
    Thommes EW, Kruse M, Kohli M, Sharma R, Noorduyn SG.
    Hum Vaccin Immunother; 2017 Apr 03; 13(4):867-876. PubMed ID: 27858509
    [Abstract] [Full Text] [Related]

  • 31. Quadrivalent influenza vaccines in low and middle income countries: Cost-effectiveness, affordability and availability.
    Hendriks J, Hutubessy RCW, Grohmann G, Torelli G, Friede M, Kieny MP.
    Vaccine; 2018 Jun 27; 36(28):3993-3997. PubMed ID: 29866617
    [Abstract] [Full Text] [Related]

  • 32. A Phase III randomised trial of the immunogenicity and safety of quadrivalent versus trivalent inactivated subunit influenza vaccine in adult and elderly subjects, assessing both anti-haemagglutinin and virus neutralisation antibody responses.
    van de Witte S, Nauta J, Montomoli E, Weckx J.
    Vaccine; 2018 Sep 25; 36(40):6030-6038. PubMed ID: 29709447
    [Abstract] [Full Text] [Related]

  • 33. A Novel Dynamic Model for Health Economic Analysis of Influenza Vaccination in the Elderly.
    Mullikin M, Tan L, Jansen JP, Van Ranst M, Farkas N, Petri E.
    Infect Dis Ther; 2015 Dec 25; 4(4):459-87. PubMed ID: 26350238
    [Abstract] [Full Text] [Related]

  • 34. Immunogenicity and safety of inactivated quadrivalent and trivalent influenza vaccines in children 18-47 months of age.
    Rodriguez Weber MA, Claeys C, Aranza Doniz C, Feng Y, Innis BL, Jain VK, Peeters M.
    Pediatr Infect Dis J; 2014 Dec 25; 33(12):1262-9. PubMed ID: 25386965
    [Abstract] [Full Text] [Related]

  • 35. Cost-effectiveness of high-dose versus standard-dose inactivated influenza vaccine in adults aged 65 years and older: an economic evaluation of data from a randomised controlled trial.
    Chit A, Becker DL, DiazGranados CA, Maschio M, Yau E, Drummond M.
    Lancet Infect Dis; 2015 Dec 25; 15(12):1459-66. PubMed ID: 26362172
    [Abstract] [Full Text] [Related]

  • 36.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 37. Cost-effectiveness of live attenuated influenza vaccine versus inactivated influenza vaccine among children aged 24-59 months in the United States.
    Luce BR, Nichol KL, Belshe RB, Frick KD, Li SX, Boscoe A, Rousculp MD, Mahadevia PJ.
    Vaccine; 2008 Jun 02; 26(23):2841-8. PubMed ID: 18462851
    [Abstract] [Full Text] [Related]

  • 38. Cost-effectiveness analysis of quadrivalent seasonal influenza vaccines in England.
    Thorrington D, van Leeuwen E, Ramsay M, Pebody R, Baguelin M.
    BMC Med; 2017 Sep 08; 15(1):166. PubMed ID: 28882149
    [Abstract] [Full Text] [Related]

  • 39. Safety and immunogenicity of an inactivated quadrivalent influenza vaccine in children 6 months through 8 years of age.
    Greenberg DP, Robertson CA, Landolfi VA, Bhaumik A, Senders SD, Decker MD.
    Pediatr Infect Dis J; 2014 Jun 08; 33(6):630-6. PubMed ID: 24445833
    [Abstract] [Full Text] [Related]

  • 40. [Cost-effectiveness analysis of quadrivalent influenza vaccination for older adults aged 60 and above in mainland China].
    Yan H, Yang J, Chen ZY, Gong H, Zhong GJ, Yu HJ.
    Zhonghua Yi Xue Za Zhi; 2021 Aug 10; 101(30):2405-2412. PubMed ID: 34404135
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 9.